Acumen Pharmaceuticals, Inc. (ABOS) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 7 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for ABOS is $7.00, representing a +161.2% upside from the current price of $2.68. Price targets range from a low of $7.00 to a high of $7.00.
